EurekAlert!

PBPK model precisely predicts drug–drug interactions between prodrug GP681 and CYP3A4 inhibitors, offering new guidance for safe influenza therapy

A physiologically based pharmacokinetic (PBPK) model developed for suraxavir marboxil (GP681) and its active metabolite ...
Science Daily

Study provides scaffold to selectively target drug breakdown process

Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
MedPage Today

Dangers to Consider in Patients Who Take Docetaxel

—A long-overdue study from Japan focused on the docetaxel-associated development of febrile neutropenia in cancer patients and its association with concomitant polypharmacy involving CYP3A4 inhibitors ...
Business Wire

Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (Blade or the Company), a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and ...
Hosted on MSN

Study provides scaffold to selectively target drug breakdown process

Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration (FDA)-approved drugs, reducing their effectiveness. However, how to prevent CYPs from ...